LY9 and ovarian cancer: Furthermore, these could predict enhanced sensitivity to immune checkpoint blockade and poly ADP ribose polymerase (PARP) inhibitors, confirming SLAMF3 as an attractive immunotherapeutic target in ovarian cancer (61).